Suppr超能文献

健康与幸福指导辅助GLP-1诱导的体重减轻。

Health and Well-Being Coaching Adjuvant to GLP-1 Induced Weight Loss.

作者信息

Sforzo Gary A, Gordon Neil F, Peeke Pamela M, Moore Margaret

机构信息

School of Health Science and Human Performance, Ithaca College, Ithaca, NY, USA (GAS).

Intervent, Savannah, GA, USA (NFG).

出版信息

Am J Lifestyle Med. 2024 Nov 19:15598276241302273. doi: 10.1177/15598276241302273.

Abstract

Glucagon-like peptide agonists (GLP-1) are highly effective anti-obesity medications. However, sustained effectiveness is potentially plagued by lack of adherence to the drug and resumption of pre-weight loss behaviors. Side effects are primarily severe gastrointestinal distress but can occasionally be more serious. Health and well-being coaching (HWC) is an important obesity intervention that can be used alongside GLP-1 prescription. HWC is documented to improve medication adherence and promote healthy behavior change. A coach who understands the complexities of rapid weight loss, specifically with GLP-1, can help the patient persist with the treatment. Moreover, the coach can assist in navigating GLP-1 side effects including undesirable loss of skeletal muscle during the weight loss period. A patient-centric and collaborative relationship seem essential to the HWC process. Specific coaching techniques are suggested for working with patients losing weight. The logical, but yet to be tested, expectation is that HWC as an adjuvant intervention to GLP-1 prescription will improve medication adherence and encourage sustained weight loss and health benefits in patients with obesity.

摘要

胰高血糖素样肽激动剂(GLP-1)是非常有效的抗肥胖药物。然而,持续有效性可能受到药物依从性差和恢复减肥前行为的困扰。副作用主要是严重的胃肠道不适,但偶尔可能更严重。健康与幸福指导(HWC)是一种重要的肥胖干预措施,可与GLP-1处方一起使用。有文献证明,HWC可提高药物依从性并促进健康行为改变。了解快速减肥复杂性(特别是使用GLP-1时)的指导人员可以帮助患者坚持治疗。此外,指导人员可以协助应对GLP-1的副作用,包括减肥期间骨骼肌意外流失。以患者为中心的合作关系似乎对HWC过程至关重要。建议采用特定的指导技巧来帮助减肥患者。合理但尚未经过检验的期望是,HWC作为GLP-1处方的辅助干预措施,将提高药物依从性,并鼓励肥胖患者持续减肥并获得健康益处。

相似文献

1
Health and Well-Being Coaching Adjuvant to GLP-1 Induced Weight Loss.
Am J Lifestyle Med. 2024 Nov 19:15598276241302273. doi: 10.1177/15598276241302273.
2
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.
Adv Ther. 2021 Jun;38(6):2821-2839. doi: 10.1007/s12325-021-01710-0. Epub 2021 May 11.
5
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies.
Diabetes Obes Metab. 2024 Sep;26 Suppl 4:16-27. doi: 10.1111/dom.15728. Epub 2024 Jun 27.
7
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management.
Curr Atheroscler Rep. 2022 Aug;24(8):643-654. doi: 10.1007/s11883-022-01041-7. Epub 2022 May 28.
8
Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?
Circulation. 2024 Oct 15;150(16):1288-1298. doi: 10.1161/CIRCULATIONAHA.124.067676. Epub 2024 Oct 14.
10
Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
Calcif Tissue Int. 2024 Feb;114(2):86-97. doi: 10.1007/s00223-023-01150-8. Epub 2023 Nov 24.

本文引用的文献

1
Exercise for Clients Taking an Anti-Obesity Medication.
ACSMs Health Fit J. 2024 May-Jun;28(3):21-26. doi: 10.1249/fit.0000000000000959.
2
GLP-1 RA for cardiometabolic risk reduction in obesity - How do we best describe benefit and value?
Am J Prev Cardiol. 2024 May 18;18:100682. doi: 10.1016/j.ajpc.2024.100682. eCollection 2024 Jun.
3
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
4
Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes.
J Manag Care Spec Pharm. 2024 Aug;30(8):860-867. doi: 10.18553/jmcp.2024.23332. Epub 2024 May 8.
7
Obesity drugs aren't always forever. What happens when you quit?
Nature. 2024 Apr;628(8008):488-490. doi: 10.1038/d41586-024-01091-8.
8
Dermatologic findings associated with semaglutide use: A scoping review.
J Am Acad Dermatol. 2024 Jul;91(1):166-168. doi: 10.1016/j.jaad.2024.03.021. Epub 2024 Mar 29.
10
Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use.
Menopause. 2024 Apr 1;31(4):266-274. doi: 10.1097/GME.0000000000002310. Epub 2024 Mar 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验